Quantbot Technologies LP Makes New $349,000 Investment in OPKO Health, Inc. $OPK

Key Points

• Quantbot Technologies LP made a new investment in OPKO Health, Inc., purchasing 210,079 shares valued at approximately $349,000.
• CEO Phillip Frost significantly increased his stake by acquiring 675,000 shares for about $891,000, bringing his ownership to over 214 million shares.
• Equities analysts have mixed ratings on OPKO Health, with a consensus rating of "Moderate Buy" and a price target of $2.75 despite a recent earnings miss.

Quantbot Technologies LP purchased a new position in OPKO Health, Inc. (NASDAQ:OPK - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 210,079 shares of the biotechnology company's stock, valued at approximately $349,000.

Other institutional investors have also modified their holdings of the company. Oak Thistle LLC acquired a new position in shares of OPKO Health in the first quarter worth $26,000. Cerity Partners LLC acquired a new position in shares of OPKO Health in the first quarter worth $36,000. Wealth Enhancement Advisory Services LLC grew its stake in shares of OPKO Health by 75.3% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company's stock worth $42,000 after acquiring an additional 12,417 shares in the last quarter. Pallas Capital Advisors LLC acquired a new position in shares of OPKO Health in the first quarter worth $43,000. Finally, Mercer Global Advisors Inc. ADV grew its stake in shares of OPKO Health by 105.6% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 43,167 shares of the biotechnology company's stock worth $63,000 after acquiring an additional 22,167 shares in the last quarter. Institutional investors and hedge funds own 64.63% of the company's stock.

Insiders Place Their Bets

In related news, CEO Phillip Md Et Al Frost purchased 675,000 shares of OPKO Health stock in a transaction that occurred on Friday, August 8th. The stock was purchased at an average cost of $1.32 per share, with a total value of $891,000.00. Following the completion of the transaction, the chief executive officer directly owned 214,676,448 shares in the company, valued at approximately $283,372,911.36. The trade was a 0.32% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 49.69% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts have commented on OPK shares. Barrington Research restated an "outperform" rating and issued a $2.25 price target on shares of OPKO Health in a research note on Thursday, May 1st. Zacks Research upgraded shares of OPKO Health from a "strong sell" rating to a "hold" rating in a research note on Thursday, August 14th. LADENBURG THALM/SH SH upgraded shares of OPKO Health to a "strong-buy" rating in a research note on Tuesday, July 8th. Finally, Wall Street Zen downgraded shares of OPKO Health from a "hold" rating to a "sell" rating in a research note on Monday, May 5th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $2.75.

OPKO Health Price Performance

Shares of OPK opened at $1.39 on Wednesday. OPKO Health, Inc. has a 1-year low of $1.11 and a 1-year high of $2.04. The stock has a market cap of $1.10 billion, a PE ratio of -5.56 and a beta of 1.19. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.41 and a quick ratio of 3.02. The firm has a fifty day moving average price of $1.34 and a 200 day moving average price of $1.46.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biotechnology company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.07). OPKO Health had a negative net margin of 26.68% and a negative return on equity of 13.17%. The company had revenue of $156.80 million during the quarter, compared to analysts' expectations of $165.74 million. During the same period last year, the firm earned ($0.01) earnings per share. OPKO Health's revenue was down 13.9% on a year-over-year basis. As a group, sell-side analysts anticipate that OPKO Health, Inc. will post -0.25 EPS for the current year.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.

Want to see what other hedge funds are holding OPK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OPKO Health, Inc. (NASDAQ:OPK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.